Marine n-3 fatty acids modulate gut microbiota in obese/diabetic mice

Marine n-3 PUFAs have been suggested to prevent the development of metabolic disorders. However, their individual role in treating hyperglyciemia and the mechanism of action regarding gut microbiome and metabolome in the context of obesity/diabetes remain unclear. We aimed to assess the effects of DHA and EPA on gut microbiota in obese/diabetic mice. Our results offer new insights into the gut microbiota-organs axis as a suitable target for treating metabolic perturbations and also suggests marine n-3 PUFAs may be a efficient therapeutic dietary supplement for obese/diabetic patients.

已有研究提示，海洋n-3多不饱和脂肪酸（marine n-3 PUFAs）可预防代谢紊乱的发生。然而，其在治疗高血糖症中的单独作用，以及在肥胖/糖尿病背景下针对肠道微生物组（gut microbiome）与代谢组的作用机制，仍未明确。本研究旨在评估二十二碳六烯酸（DHA）与二十碳五烯酸（EPA）对肥胖/糖尿病小鼠肠道微生物群（gut microbiota）的影响。研究结果为将肠道微生物-器官轴作为治疗代谢异常的适宜靶点提供了新的见解，同时表明海洋n-3多不饱和脂肪酸或可成为肥胖/糖尿病患者的高效治疗性膳食补充剂。